|
1
|
Alifieris C and Trafalis DT: Glioblastoma
multiforme: Pathogenesis and treatment. Pharmacol Ther. 152:63–82.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ellis HP, Greenslade M, Powell B, Spiteri
I, Sottoriva A and Kurian KM: Current challenges in glioblastoma:
Intratumour heterogeneity, residual disease, and models to predict
disease recurrence. Front Oncol. 5:2512015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jovčevska I, Kočevar N and Komel R: Glioma
and glioblastoma - how much do we (not) know? Mol Clin Oncol.
1:935–941. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kapoor A, Mohindra S, Singla N, Sodhi HB,
Chatterjee D and Gupta SK: Multiple glioblastoma: A diagnostic
challenge and controversies in management. Neurol India.
63:449–452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang M, Ye G, Li J and Wang Y: Recent
advance in molecular angiogenesis in glioblastoma: The challenge
and hope for anti-angiogenic therapy. Brain Tumor Pathol.
32:229–236. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cloughesy TF, Cavenee WK and Mischel PS:
Glioblastoma: From molecular pathology to targeted treatment. Annu
Rev Pathol. 9:1–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guarnieri DJ and DiLeone RJ: MicroRNAs: A
new class of gene regulators. Ann Med. 40:197–208. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Erson AE and Petty EM: MicroRNAs in
development and disease. Clin Genet. 74:296–306. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao S and Liu MF: Mechanisms of
microRNA-mediated gene regulation. Sci China C Life Sci.
52:1111–1116. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nelson KM and Weiss GJ: MicroRNAs and
cancer: Past, present, and potential future. Mol Cancer Ther.
7:3655–3660. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kohlhapp FJ, Mitra AK, Lengyel E and Peter
ME: MicroRNAs as mediators and communicators between cancer cells
and the tumor microenvironment. Oncogene. 34:5857–5868. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang J, Chen J and Sen S: MicroRNA as
biomarkers and diagnostics. J Cell Physiol. 231:25–30. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lan H, Lu H, Wang X and Jin H: MicroRNAs
as potential biomarkers in cancer: Opportunities and challenges.
Biomed Res Int. 2015:1250942015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Møller HG, Rasmussen AP, Andersen HH,
Johnsen KB, Henriksen M and Duroux M: A systematic review of
microRNA in glioblastoma multiforme: Micro-modulators in the
mesenchymal mode of migration and invasion. Mol Neurobiol.
47:131–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xue J, Niu YF, Huang J, Peng G, Wang LX,
Yang YH and Li YQ: miR-141 suppresses the growth and metastasis of
HCC cells by targeting E2F3. Tumour Biol. 35:12103–12107. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
van Jaarsveld MT, Helleman J, Boersma AW,
van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, Mathijssen RH,
Berns EM, Verweij J, et al: miR-141 regulates KEAP1 and modulates
cisplatin sensitivity in ovarian cancer cells. Oncogene.
32:4284–4293. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tejero R, Navarro A, Campayo M, Vinolas N,
Marrades RM, Cordeiro A, Ruiz-Martinez M, Santasusagna S, Molins L,
Ramirez J and Monzó M: miR-141 and miR-200c as markers of overall
survival in early stage non-small cell lung cancer adenocarcinoma.
PLoS One. 9:e1018992014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu
X, Xiao P, Shi H, Wang R, Chen L, et al: miR-141 is a key regulator
of renal cell carcinoma proliferation and metastasis by controlling
EphA2 expression. Clin Cancer Res. 20:2617–2630. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Feiden S and Feiden W: WHO classification
of tumours of the CNS: Revised edition of 2007 with critical
comments on the typing und grading of common-type diffuse gliomas.
Pathologe. 29:411–421. 2008.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Du Y, Xu Y, Ding L, Yao H, Yu H, Zhou T
and Si J: Down-regulation of miR-141 in gastric cancer and its
involvement in cell growth. J Gastroenterol. 44:556–561. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vrba L, Jensen TJ, Garbe JC, Heimark RL,
Cress AE, Dickinson S, Stampfer MR and Futscher BW: Role for DNA
methylation in the regulation of miR-200c and miR-141 expression in
normal and cancer cells. PLoS One. 5:e86972010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cheng H, Zhang L, Cogdell DE, Zheng H,
Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR and Zhang W:
Circulating plasma MiR-141 is a novel biomarker for metastatic
colon cancer and predicts poor prognosis. PLoS One. 6:e177452011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang Z, Huang D, Ni S, Peng Z, Sheng W
and Du X: Plasma microRNAs are promising novel biomarkers for early
detection of colorectal cancer. Int J Cancer. 127:118–126. 2010.
View Article : Google Scholar : PubMed/NCBI
|
